Washington Research Foundation Awards Additional $1M to Fred Hutchinson Cancer Center Supporting Innovative Technology Commercialization Research in Life Sciences
Retrieved on:
Tuesday, December 20, 2022
BV, Bacterial vaginosis, Immunotherapy, Patient, Business development, Neoplasm, WRF, Paddison, Health, University, Technology transfer, Regulatory T cell, Inflammation, Doctor of Philosophy, Cancer, Antigen, University of Washington Department of Bioengineering, Research, Gujral, Pharmaceutical industry, Vaccine, Fred Hutchinson Cancer Research Center
SEATTLE, Dec.20, 2022 /PRNewswire-PRWeb/ -- Last year, Washington Research Foundation (WRF) and Fred Hutchinson Cancer Center (Fred Hutch) launched a new collaborative funding program to advance technologies that can have a significant impact on improving the health of communities. Since then, WRF has awarded two cycles of $750,000 in funding that have supported 11 technology commercialization projects at Fred Hutch with grants between $50,000 and $250,000. Today, WRF announces an additional $1 million to Fred Hutch to continue support for the program.
Key Points:
- Since then, WRF has awarded two cycles of $750,000 in funding that have supported 11 technology commercialization projects at Fred Hutch with grants between $50,000 and $250,000.
- Today, WRF announces an additional $1 million to Fred Hutch to continue support for the program.
- "The additional funding from WRF allows us to continue operating the program and supporting researchers who are on the frontlines of innovative science."
- Washington Research Foundation (WRF) supports research and scholarship in Washington state, with a focus on life sciences and enabling technologies.